In the second wave of SARS-CoV-2 infection in the UK, when corticosteroids were the established treatment for SARS-CoV-2 infections, in secondary analyses, we compared the features of people with known T2DM who required insulin as a new treatment in the first wave of SARS-CoV-2 infection (n = 39) in April–March 2020 in the UK with those with known T2DM who also required insulin as a new treatment when hospitalised in the second wave of SARS-CoV-2 infection (n = 43) (December 2020–January 2021). Here, INS is linked to type 2 diabetes mellitus.